Special Issue

Topic: Advanced Research on Molecular Mechanisms of Cancer Drug Resistance

A Special Issue of Cancer Drug Resistance

ISSN 2578-532X (Online)

Submission deadline: 1 Oct 2024

Guest Editor(s)

Prof. Dr. Chenglai Xia
Foshan Maternity and Chlid Healthcare Hospital, Foshan, Guangdong, China.
Prof. Dr. Li-Ying Ma
School of Pharmacy, Zhengzhou University, Zhengzhou, Henan, China.

Special Issue Introduction

The tumor-resident microbiota has been linked to cancer drug resistance, and manipulation of this microbiota is a novel strategy for the prevention and treatment of cancer drug resistance. Some microbiota demonstrate antitumor activity, thereby improving the tumor microenvironment, activating immune cells including dendritic cells, helper T cells, natural killer cells, and cytotoxic T cells, and upregulating the secretion of pro-tumor immune cytokines such as interleukin-2 and interferon. Tumor-resident microbiota and specific metabolites play crucial roles in designing anticancer resistance drug and their targeted delivery.

Keywords

Tumor-resident microbiota, Immune checkpoint inhibitors, microbiota metabolites, anticancer drug design, drug targeted delivery

Submission Deadline

1 Oct 2024

Submission Information

For Author Instructions, please refer to https://www.oaepublish.com/cdr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=CDR231230
Submission Deadline: 1 Oct 2024
Contacts: Fiona Zhao, Assistant Editor, Fiona@oaeservice.com

Published Articles

Coming soon
Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/